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Abstract 
 Estrogenic compounds have important pharmaceutical and toxicological effects on 
humans.  Pharmaceutically, estrogens can be used to treat diseases such as breast cancer.  
Toxicologically, estrogens are known to affect the growth and development of young girls.  
Understanding the estrogenic properties of a target compound would allow for compounds to be 
assessed as pharmaceuticals and as environmental contaminants. 
 Current methods for measuring estrogenicity involve the use of animal models.  A model 
organism is grown, treated with the test compound, sacrificed and autopsied.  For the model to 
provide significant data, the amount of animal models used is significant.  The amount of 
animals needed to conduct a high-throughput screening is time prohibitive and economically 
unviable. 
 In this work, a high-throughput screening system for determining the estrogenicity of a 
compound is proposed.  This method uses a human estrogen receptor beta and a thymidylate 
synthase reporter system in Escherichia coli, in order to relate the growth of cells to the 
concentration and estrogenicity of a compound.  The biological, robotic and data processing 
aspects of the assay were validated initially.  Once validated, this system was used to test thirty 
compounds.  The high-throughput screening system could distinguish between estrogen agonists 
and non-agonists.  The system determined that 7 compounds in the test library were estrogen 
agonists.  
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Introduction 
Estrogens are hormones or hormonal compounds that function in many critical metabolic 
pathways in the human body [1].  Estrogen compounds have several important roles in human 
development, including roles in sexual differentiation and roles in the onset of puberty. The 
presence of estrogen in vivo is regulated by the endocrine system, which uses the hypothalamus, 
the pituitary gland and the gonads to control the concentration of estrogen in the body through all 
stages of development.  Estrogens plays important roles in several important diseases, including 
hypospadias, testicular cancer, breast cancer, and prostate cancer. 
 When estrogen-like compounds enter the human body, they can affect the function of 
estrogen pathways [2].  These compounds interfere with estrogen pathways in multiple ways: by 
altering normal estrogen transportation, by interfering with estrogen synthesis, or by 
competitively binding with native estrogen hormone receptors.  Estrogen-like compounds can 
affect the normal growth and development of humans, either by altering the proper expression of 
secondary sex characteristics or by altering the developmental cycle of humans. 
 Estrogen-like compounds have important function in the treatment of diseases such as 
breast cancer [3].  Because estrogen-like compounds can bind to hormone receptors, they can 
have a pharmacological effect on tissues which express the estrogen hormone receptor.  
Therefore, compounds can be screened for their estrogenic properties to determine potential hits 
for novel pharmaceutical compounds. 
 Some environmental compounds are known estrogen-like compounds or are suspected to 
be estrogen-like compounds [4].   Two compounds of this nature are dichlorodiphenyl-
trichloroethane (DDT) and bisphenol A (BPA).  DDT, a commonly used pesticide that is 
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currently banned, has been shown to possess estrogenic properties, while some of DDT’s 
breakdown products possess estrogenic or androgenic properties [8].  Bisphenol A has been 
shown in several assays to have estrogenic properties, but the extent of these qualities is highly 
controversial.  Estrogen-like compound levels in drinking water has been attributed to a 
decreasing age in puberty onset in prepubescent girls [4]. 
The estrogenic properties of a compound cannot be easily determined.  It is not possible 
to predict the hormonal activity of a novel compound from inspecting its chemical structure.   
Figure 1 below shows the chemical structure of estradiol, the human estrogen hormone, DDT 
and bisphenol A.  Despite all three compounds possessing estrogenic properties, their chemical 
structures vary greatly. 
 
Figure 1: Representative Estrogenic Compounds 
Animal models are typically used to assess the estrogenic properties of a compound [4].  
One animal model frequently used is the rat [5].  Two in vivo tests for estrogenic properties of 
molecules with rat models involve measuring the uterine wet weight and measuring vaginal 
epithelial cell cornification [6].  Rats are raised and treated with the compound of interest.  When 
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the rats reach maturity, they are sacrificed and autopsied to measure the property of interest.  
These methods produce false positive results with non-estrogenic compounds such as 
testosterone and fail to produce positive results with weaker estrogenic compounds.  Another 
animal model used to determine the estrogenic properties of a compound is rainbow trout [7].  
Rainbow trout are grown for 21 days with the compound of interest.  They are then sacrificed 
and autopsied to measure their weight and plasma vitellogenin concentration.  This method is 
highly dependent on the growth of the fish.   
In addition to the scientific limitations of these methods, there are practical limitations 
which prevent the adaptation of these methods to high-throughput screening.  First, a large 
inventory of laboratory test animals must be kept and maintained.  These animals must be the 
proper age and weight in order to use them in testing.  The animals must also be kept at 
consistent conditions, in order to control for the effect of food and living conditions on the 
response [6].  The costs of maintaining these animals at the proper condition for testing can be 
significant.  In addition, for the testing to yield significant and precise results, large sample sizes 
must be used [6,7].  Using large sample sizes increases the cost greatly. 
Second, animal research requires written proposals and approval from an institutional 
review board.  Requesting approval for testing a large quantity of potentially estrogenic 
compound in an initial screening experiment would be very time-consuming to perform.  The 
financial costs of keeping laboratory animals and the time cost of seeking regulatory approval 
significantly hinder the potential of using laboratory animals in high-throughput estrogenic 
screening applications. 
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Background 
In order to supplement estrogen testing methods and reduce the need for animal models 
in preliminary estrogen testing, additional testing methods are needed.  The method needs to 
show a quick response to environmental estrogens, show a difference in response to strong and 
weak estrogens, and show an easily measurable, quantifiable response.  Bacterial cells grow 
quickly and grow in response to their environment.  Therefore, bacterial sensor cells (biosensors) 
that sense environmental estrogens and grow in to response to them would have the necessary 
properties to measure the estrogenic properties of compounds quickly and efficiently.  
Biosensors have been proposed as a supplementary tool to animal models for compound testing 
[9].  By coupling the growth of bacteria with the receptor phenotype, the biosensor only 
demonstrates growth and activity when it is exposed to an estrogenic compound. 
Biosensor Mechanism of Action 
The biosensor was constructed using Escherichia coli D1210ΔthyA, a bacterial knockout 
strain which lacks native thymidylate synthase (TS) enzyme function [9].   Without TS enzyme 
function, the knockout strain cannot synthesize new DNA and is unable to grow in minimal 
media.  Thymidylate synthase catalyzes the reaction of 5,10-methenyltetrahydrofolate (MTHF) 
and deoxyuridine monophosphate (dUMP) to form dihydrofolate (DHF) and thymidine 
monophosphate (dTMP) [10].  Figure 2 on the next page shows the thymidylate synthesis 
reaction cycle [11].  Without TS enzyme, DNA cannot be synthesized, which prevents cell 
replication.  In rich media supplemented with thymine, the production of dTMP using the TS 
enzyme is not needed, because the cell can combine thymine directly with deoxyribose to create 
dTMP.  In minimal media lacking thymine, the cells are unable to synthesize DNA and are 
unable to perform cell division. 
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Figure 2: Thymidylate synthase reaction cycle [11] 
Intein Mechanism of Action 
 Inteins are self-excising protein segments that are found in cells and viruses [12].  
Naturally, inteins self-catalyze and remove themselves from a longer protein segment.  In 
addition, they connect the segment attached to the carbon side (c-terminus) and the segment 
attached to the nitrogen side (n-terminus) with a peptide bond.  This creates a smaller protein 
segment.  Inteins function similarly to regulatory proteins, which change their splicing pattern in 
response to the environment [13]. 
 Inteins are important tools in biotechnology [12].  By engineering the natural properties 
of wild-type inteins, proteins can be engineered to splice in response to specific environmental 
conditions, such as temperature, concentration or conformation.  Inteins can be engineered to 
alter their splicing patterns, allowing splicing at only one terminus or at neither terminus.  One 
application of inteins in bioengineering is protein purification.  Proteins can be engineered to 
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contain purification tags that cleave at one terminus after purification, leaving only the desired 
protein.  In the biosensor application, the intein was used to couple the activity of TS to the 
human estrogen receptor beta (ERβ) hormone receptor. 
Biosensor Construction 
After selecting the initial knockout strain, a gene had to be constructed to introduce the 
TS enzyme and the hormone receptor to the cells.  A schematic of the completed gene, 
pMIT::ERβ*, and the resulting protein is shown on the next page in figure 3.  In constructing the 
gene of interest, several issues had to be resolved to allow for proper expression of the final 
protein [14].  First, the receptor could face issues with proper folding.  When a protein is 
synthesized in a non-native host, its ability to properly fold can be compromised, due to 
differences in the cell’s microenvironment.  Small changes in cytoplasmic concentrations can 
prevent the proper folding of the receptor, altering its function.  Second, the protein of interest 
may not be soluble in the new host.  Again, this is a result of differences between the new host’s 
cytoplasmic environment is the native host’s cytoplasmic environment.  Third, the yield of the 
protein may be high enough to allow for a proper response. 
In order to assist the protein in properly folding, a gene fusion was used.  The gene fusion 
connects the gene of interest with the intein.  By inserting the gene in between two segments of 
the intein gene, the target protein will be assisted in folding by the intein [14].  In order to assist 
in the solubility of the protein, a maltose binding protein (MBP) tag was used.   MBP is a very 
soluble protein.  By fusing the MBP to the intein system, the solubility of the protein increases.  
In addition to increasing the solubility of the target protein, the MBP fusion also increases the 
activity of the protein [14]. 
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For this cell, the RecA intein from Mycobacterium tuberculosis was selected.  In between 
the c-terminus and n-terminus segments of the intein, the human ERβ receptor gene is inserted.  
The TS enzyme was added to the c-terminus of the RecA intein.  MBP was added before the n-
terminus of the intein.  Two important amino acids were changed in the gene of interest.  The 
initial cysteine in the n-terminus segment was changed to alanine, and the final asparagine in the 
c-terminus segment was changed to alanine.  These mutations prevent the intein from splicing 
and altering the DNA.  After these mutations, the protein allows the binding of an estrogenic 
compound to the human ERβ receptor to increase the activity of the TS enzyme.  Finally, a tac 
promoter was used to facilitate transcription of the gene in the E. coli cells. 
 
Figure 3: Protein fusion of estrogen receptor and TS [14] 
Biosensor Response to Compounds 
The cells show a dose-response relationship with the presence of estrogenic compounds.  
Figure 4 below shows a representative dose-response curve using the biosensors and a human 
estrogen receptor agonist [14].  When the logarithmic concentration of the estrogenic compound  
 
Figure 4: Representative dose-response curve [14] 
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added to the cells is compared to the growth of cells, a sigmoidal curve is present.  Because the 
concentration is related to the probability of a compound-receptor interaction, the response from 
the cells will not be linear [15].  From the sigmoidal curve, the estimated concentration at which 
50 percent of the receptors respond (EC50) can be determined.  By comparing the EC50 of 
compounds, the agonistic effect of the compounds on human ERβ receptors can be compared. 
Objective 
 The main objective of this work was to create and validate an assay which could detect 
the estrogenic properties of a small molecule without the use of animal testing.  This system 
needed to be able to reproduce known estrogenic properties of compounds and measure the 
estrogenic properties of uncharacterized compounds.  In addition, the assay needed to conform to 
the requirements of the Interagency Coordinating Committee on the Validation of Alternative 
Methods (ICCVAM).  The ICCVAM has established stringent requirements for any non-animal 
assay to be considered an alternative to animal testing [16].  These requirements include 
experimental design considerations and chemical considerations. 
 In addition to stringent assay requirements, the ICCVAM requires the testing of many 
reference compounds.  These reference compounds contain strong agonists, weak agonist and 
antagonists.  Many compounds are pharmaceuticals, while some are commonly used 
environmental compounds such as pesticides.  A list of the compounds required by the ICCVAM 
for testing and their expected behavior are included in appendix A.  Some of the compounds that 
were listed by the ICCVAM as test compounds were not tested, however.  Many of the 
compounds, due to their hormonal and pharmacological properties, are controlled substances, 
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which could not be easily purchased.  Other compounds were unable to be shipped, due to their 
hazardous nature.  Because of this, only a select number of compounds could be tested. 
Methods 
The validation and testing of the assay can be divided into four main phases.  In the first 
phase, the biological conditions of the assay were developed.  This includes the growth media, 
the amount of times for each growth phase and the inoculation amounts.  In the second phase, the 
liquid handling robots were validated.  This was accomplished by writing and testing calibration 
programs, which could verify the amount of liquid that was pipetted in each step.  In the third 
phase, the plate reader was verified for its accuracy and precision. Next, the data processing 
programs had to be modified to allow for higher throughput processing.  Once the validation was 
complete, the target compounds were tested in the assay. 
Biological Validation 
 Initially, the ERβ biosensors were grown on Petri dishes for 18 hours at 37 degrees 
Celsius.  The plates were made using Luria-Bertani broth agar (LB agar) fortified with ampicillin 
and thymine.  Specific recipes for the media used are located in appendix B.  LB agar is a rich, 
undefined media that provides the cells with a carbon and nitrogen source, allowing the cells to 
grow.  The ampicillin is added to select for cells that keep their plasmid during replication.  
Without selective forces keeping evolutionary pressure on maintaining the plasmid, the cells can 
spontaneously lose the plasmid and lose the ERβ hormone receptor and TS enzyme.  Thymine is 
added to assure that the cells can grow in the media without risking thymineless death, a rapid 
cell death process that is caused by a lack of thymine for DNA synthesis. 
 10  
 After the growth on plates, the cells were grown in liquid media at 37 degrees Celsius for 
between 6 and 12 hours.  The liquid media contained Luria-Bertani broth (LB media), thymine 
and ampicillin.  The LB media is a rich media, similar to LB agar, which provides a carbon and 
nitrogen source to the bacteria.  The ampicillin provides selective pressure towards the cells 
keeping their plasmid, and the thymine assures that the cells can grow in the media.  To seed the 
liquid media, a single colony was used.  By using a single colony, the homogeneity of the cells 
seeding the liquid culture can be assured.  A single colony on a petri dish must arise from a 
single cell, so by selecting a single colony, the cells must be a single strain. 
 The liquid cells were grown until they reached the late growth phase.  This assured that 
the cells were in high concentration, but that no cells had begun to die.  Figure 5 below shows a 
representative bacterial growth curve.  As soon as the bacteria reach the stationary phase, the  
 
Figure 5: Representative bacterial growth curve [18] 
 
 11  
cells begin to die.  Transferring dead cells is not desired, because dead cells will affect the 
optical density reading but not respond to estrogenic compounds.  To determine the current 
growth phase of the cells, the optical density (OD) of the cells was determined.  The OD reading 
was done at 600 nanometers.  600 nanometers is typically used to measure E. coli growth in LB 
broth because no components of the media absorb light at that wavelength [17].  In addition, the 
OD at this wavelength is proportional to the scattering of light by the bacteria, which is directly 
proportional to the number of cells in the broth.   
 The cells were then transferred to thymine free media (-Thy).  –Thy is a chemically 
defined, minimal media that contains specific quantities of chemical supplements necessary for 
growth.  Other types of growth media, such as LB media, provide inconsistent amounts of a wide 
variety of chemical supplements.  The specific nature of rich chemical components is impossible 
to determine, because the components are produced by incomplete digestion reactions that break 
chemicals down in an uneven manner.  Although LB media components are less expensive and 
provide trace components which cells may need for growth, they are not preferred for the final 
growth phase.  In the final phase, the exact composition of the media must be known, in order to 
assure the only component affecting the ERβ hormone receptor is the estrogenic compound.  
Also, no thymine can be present in the final growth media.  Without thymine, cell growth can 
only occur if the ERβ hormone receptor is bound and TS is released. 
 The LB media with cell growth is added to –Thy media.  A ratio of 1 to 200 is used to 
add the cells.  This ratio assures that enough cells are added to observe a response, but that the 
concentrations of other LB media components are minimal.  The –Thy media with cells is then 
pipetted into 96-well plates.  The compounds of interest are also added to –Thy media in the 
plates.  The compounds of interest are added as a dimethyl sulfoxide (DMSO) solution.  To 
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avoid the toxic effect of DMSO on the cells, the solution is added such that the final 
concentration of DMSO in the cell solution is one percent [19].  
 Once a 96-well plate is prepared, it is incubated at 34 degrees Celsius.  To determine the 
ability for cells to grow in the plates, the growth of cells in the presence of 17β-estradiol (E2), 
triiodothyronine (T3) and tiratricol (Triac) was measured.  The time for an optimum dose-
response curve to be observed had to be determined empirically.  Initially, the optimum growth 
period was assumed to be between 12 and 21 hours.  By measuring the OD of the bacteria in the 
96-well plates at varying growth times, the growth could be correlated to the amount of growth.  
If the growth time was too short, the dose-response curve would not have enough points above 
the growth increase to assure that the fitted curve is sigmoidal.  If the growth time was too long, 
the bacteria would grow too much, and the curves would be too flat.  As a result, the dose-
response curves would be less pronounced, and curve fitting would be much more difficult.  
Figure 6 below contains a representative dose-response curve with the desired properties. 
 
Figure 6: Representative dose-response curve 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
-14 -12 -10 -8 -6 -4 -2 0
R
es
p
o
n
se
 
log([Agonist]) (M) 
 13  
Liquid Handling Validation 
 Once the biological aspects of the assay were confirmed, the liquid handling robot was 
validated to assure that the amounts of liquid transferred by the robot were accurate.  To do this, 
the absorbance of tartrazine dye at varying concentrations was tested.  Tartrazine was selected as 
the dye of interest because it has a distinct absorbance peak, because it is non-toxic and because 
it is a commonly used calibration dye [20]. The slope of the calibration curve was used to 
determine if the dye was being added in precise and consistent amounts.   For calibration, two 
liquid handling tools were considered: a 200 microliter tool and a 20 microliter tool.  If the 
regression coefficient was indistinguishable between hand pipetting and robotic pipetting, the 
liquid handling robot was considered to be precise. 
Absorbance Validation 
 To verify the precision of the plate reader, the extinction coefficient of the tartrazine was 
experimentally determined and compared to literature values.  The absorbance of the dye can be 
determined using the Beer-Lambert law.  Equation 1 below shows the relationship between 
absorbance and concentration of dye. 
             (1) 
 In this form of the Beer-Lambert law, the absorbance is determined experimentally.  The 
path length and concentration are known.  By measuring the absorbance as a function of 
concentration, the extinction coefficient of the dye can be determined.  The experimentally 
determined coefficient can be compared to the literature value to determine the accuracy of the 
plate reader. 
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Data Processing 
 Once the method is validated and data is collected, the data must be processed.  Because 
each dilution plate was repeated in triplicate and each experiment used multiple dilution plates, 
there was a significant amount of data to process for each experiment.  In order to construct 
dose-response curves for each estrogenic compound tested, a Matlab program was used.  This 
program read a data file and calculated average absorbances and standard deviations of the 
absorbances.  Next, the program fit the data to the Hill equation, an equation widely used in data 
modeling because of its flexibility in biological and pharmaceutical applications [21].  In this 
case, the Hill equation had the form of a 4-factor logistic equation, corresponding to a sigmoidal 
curve.  Equation 2 below shows the equation used to fit the data. 
    
   
         
      (2) 
In order to fit the data to the curve, non-linear regression was used to determine the four 
constants.  In addition, the EC50 of each curve was calculated.  Each plate was graphed.  
Appendix B contains the Matlab programs used to model and graph the data. 
 The program will fit all data to a sigmoidal curve, regardless of the correctness of a 
sigmoidal fit.  Therefore, each fit was visually inspected to determine the correctness of the 
sigmoidal fit.  Several rules were applied to determine the validity of the sigmoidal fit.  First, the 
EC50 had to be in a concentration within the data recorded.  If the program predicted an EC50 
beyond the investigated concentration, the EC50 value was disregarded.  Second, if the fit 
showed antagonistic behavior, rather than agonistic behavior, the fit was disregarded.  Because 
the assay cannot induce antagonism, any antagonistic behavior that was fitted is the result of data 
fitting errors.   
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Results 
Biological Validation Results 
 The initial growth of bacteria in LB agar Petri dishes was successful.  Growth of 
individual colonies across the plate was observed.  The colony morphology was consistent across 
the plate.  Therefore, the bacteria were considered to be a single species that contained the 
desired plasmid.   
 A large variation in growth time required for the liquid broth to reach an optimal OD was 
observed.  This challenged the consistency of the experimental protocol.  The hypothesized 
source of this variation was the variation in colony size used to seed the liquid media.  Because a 
single colony contains between 3,000,000 and 5,000,000 cells and because cell growth is 
exponential, the initial amount of bacteria seeded alters the growth kinetics greatly.  To 
overcome this variance, an additional culture step was added.  The single growth step in liquid 
media was replaced with two steps using the same LB media fortified with thymine and 
ampicillin.  The first step was an overnight growth for 12 to 14 hours.  After this time, cells were 
consistently in the stationary phase of growth.  The cells were then transferred in a one to 100 
dilution into fresh LB media fortified with thymine and ampicillin.  By adding this step, the 
second culture time was between 2.5 to 3.5 hours.  The additional culture step greatly increased the 
protocol’s consistency. 
 The plate reader was able to successfully read plates with bacterial growth.  In the 
presence of a 96-well plate, the plate reader could distinguish between wells without growth and 
wells with growth.  Until the accuracy of the plate reader could be robustly determined, the 
reader could be used to determine the presence of a strong dose-response curve and no dose-
response curve. 
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 Dose-response curves for the biosensors were constructed after 18 hours of growth for 
E2, T3 and Triac.  Figure 7 below shows the dose-response curve for E2.  Dose-response curves 
for all three compounds are included in appendix C.  The figure shows that a dose-response 
relationship exists between the human ERβ receptor beta and E2.  Because E2 is the natural 
analog of the human ERβ receptor, the result confirms the success of the protocol.  Table 1 
below shows the results for all three compounds.  Because T3 and Triac are thyroid hormone 
analogues, there should be no effect on the ERβ receptor.  Because no effect is observed, the 
biosensor can discriminate between estrogenic and non-estrogenic compounds. 
 
 
Figure 7: Dose-response curve for E2 
Table 1: Dose-response curve summary 
Compound E2 T3 Triac 
Does-Response Curve Yes No No 
Expected Relationship Yes No No 
 
ERβ-H Dose-Response Curve – E2 - 34 C - 18 Hours - 8/22/11 
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Dose-response curves for the biosensors were constructed after 12, 18 and 21 hours of 
growth in the presence of E2.  These curves are located in appendix C.  Figure 8 below contains 
the dose-response curve for 12 hours of growth.  The dose-response curve is not fully resolved, 
so the growth time is not long enough.  As the growth time is increased, the dose-response curve 
becomes more resolved.  As the time is increased to 18 hours and greater, the dose-response 
curve becomes overgrown, and the sigmoidal curve becomes more difficult to resolve.  The 
optimal growth time was determined to be 15 hours.  
 
 
Figure 8: Dose-response curve for E2 for 12 hours growth 
 After the optimal growth time for the cells was determined, the cells were tested with 
weaker agonists.  By testing with weaker agonists, the sensitivity of the assay could be initially 
tested.  The compounds tested were E2, bisphenol A and meso-hexestrol.  The dose-response 
curves for these tests are located in appendix C.  The EC50 values for all three of these 
compounds are located in table 2 on the next page.  E2 and meso-hexestrol have similar EC50 
ERβ-H Dose-Response Curve – E2 - 34 C - 12 Hours - 8/22/11 
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values.  Bisphenol A did not have an EC50 value.  These preliminary results showed that the 
assay was very sensitive to weaker agonists.  Because the biosensors responded to not only 
strong estrogens but also weaker estrogens, the cells could be used to screen for estrogenic 
properties.  The false negative result for bisphenol A was attributed to inadequacies in the 
experimental procedure, discussed above.  The protocol changes, which were not adopted until 
after the initial testing, removed these false negatives.  This result will be discussed in the 
screening results section. 
Table 2: EC50 values for weaker estrogenic compounds 
Compound EC50 (M) 
E2 9.1*10
-7 
Bisphenol A None 
meso-hexestrol 9.5*10
-7 
 
Liquid Handling Results 
 Calibration curves for the liquid handing robot are located in appendix D.  The maximum 
concentration of dye had to be determined.  If the dye concentration was too high, the plate 
reader cannot read the concentration accurately.  A 20-fold dilution of the initial dye stock was 
determined to read within the limits of the plate reader.  Hand pipetting established baseline for 
precision requirements for the robot.  Figure 9 on the next page contains the hand pipetting curve 
for 20 to 200 microliters of dye solution.  The graph displays a linear trend.  Because the trend is 
linear, the amount of dye being transferred is considered precise. 
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Figure 9: Liquid handling hand calibration curve 
 For each calibration, 8 replicates were made.  This number was chosen because there are 
8 rows on a single 96-well plate.  Table 3 below summarizes the results of the calibration 
experiments.  Each trial had a comparable slope.  The standard deviations for each trial were also 
small.  Finally, the R
2
 value of each fit is high.  The 1-20 microliter tool had a lower R
2
 value 
than the other two calibrations.  This is expected, because the concentration of dye in this 
calibration is very low.  Because the calibrations show consistent and accurate data, the liquid 
handling robot can be accurately used to transfer liquids. 
Table 3: Liquid handling calibration results summary 
Experiment Slope R
2 
value Standard deviation (average) 
Hand calibration 946.61 0.9979 0.038 
20-200 microliter Tool 978.53 0.9995 0.025 
1-20 microliter tool 997.76 0.9709 0.019 
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Absorbance Validation Results 
 The slopes of regressed lines from liquid handling calibration were used to verify the 
extinction coefficient of tartrazine dye.  Tartrazine has an extinction coefficient of 2.5±0.2*10
4
 
liters per mole centimeter [22].  By knowing the slope of the absorption curve and the path 
length of the plate reader, the extinction coefficient can be calculated.  One issue with this 
method is that the plate reader used incorporates a feature called path length correction [23]. Path 
length correction scales the absorption value to account for the varying path lengths possible in 
96-well plates and to account for other experimental factors.  Therefore, instead of calculating 
the true path length of the samples and comparing to the actual plate geometry, a “corrected path 
length” can be calculated and compared.  Table 4 below contains the calculated corrected path 
lengths for each calibration trial.  Because the corrected path lengths are very similar, the plate 
reader can be used to accurately read cell growth on the media. 
Table 4: Absorbance validation parameters 
Experiment Slope (absorbance/(mol/L) Extinction coefficient 
(L/mol*cm) 
Corrected path 
length (cm) 
Hand calibration 946.61 2.5*10
4 
0.038 
20-200 microliter Tool 978.53 2.5*10
4
 0.039 
1-20 microliter tool 997.76 2.5*10
4
 0.040 
Screening Results 
 Thirty compounds were tested.  These compounds came from the list in appendix A.  Each 
compound was grown with three controls: E2, genestein and ICI182780.  E2 is an estrogen agonist and a 
positive control.  Genestein is a weak agonist and a positive control.  ICI182780 is an estrogen antagonist 
and a negative control.  To assure that growth was not plate-dependent, the controls were run on each 
plate.  The dose-response curve of each compound was graphed with its corresponding controls.  If the 
controls failed to work, the test was considered a failure. 
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One issue that quickly arose was the rejection of inaccurate dose-response curves.  This 
inspection was done manually to assure that the curves rejected were indeed false matches.  
Figure 10 below contains a representative graph of this case.  A dose-response curve was 
rejected if the data did not show a significant response or if the response was antagonistic.  
Appendix E contains all the dose-response curves for all thirty compounds.  Appendix F contains 
the results summarized in a table. 
 
Figure 10: Representative dose-response curve with false match 
Seven estrogen agonists were identified with the assay.  There were 23 compounds that 
were identified as compounds with non-agonistic behavior.  On all the trials, the controls 
performed as expected.  E2 and genestein behaved as an agonist in all cases.  ICI 182,780 
behaved as a non-antagonist in all cases.  Because the controls behaved as expected, the 
screening experiment performed as expected. 
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Comparison with Previous Work 
 Previous work involving the estrogen biosensor was completed using culture tubes, rather 
than 96-well plates, for growing bacteria [14].   The OD of the bacteria was measured, and dose-
response curves were constructed from the data.  Figure 11 below shows the dose-response 
curves for E2 and genestein.  Both of these compounds have an EC50 in the concentration range 
of 0.1 micromoles per liter.  These results agree with the results from trial controls.  
 
Figure 11: Dose-response curves for E2 and genestein [14] 
Conclusions 
 The screening system performs well with controls.  The system was able to identify 
estrogen agonists without the use of animal testing.  In order to verify the results, however, 
animal models could be used to test the compounds which show an agonistic relationship.  By 
eliminating out several compounds as estrogen agonists before using animal models, this system 
provides a preliminary estrogen screening method that provides several benefits to 
pharmaceutical and toxicological research.  
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 In order for this screening system to be used in a high-throughput system, the experiment 
will have to be scaled to function with higher count well plates, such as 384- or 1596-well plates.  
The biological aspects of the experiment, such as growth media composition, will not be 
affected.  An alternative liquid handling system will need to be adopted and validated.  The 
mixing dynamics of 384- and 1596-well plates need to be investigated, before they are used in 
the system.  Finally, a plate reader compatible with higher well count plates will need to be used.  
Other than the validation necessary for new equipment, the system remains essentially 
unchanged.   
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Appendix A: ICCVAM Compounds 
Table 5: ICCVAM compound list 
Compound Expected Behavior 
17-α-ethinyl estradiol Strong ER agonist 
Diethylstilbestrol Strong ER agonist 
17α-estradiol ER agonist 
17β-estadiol Strong ER agonist 
Meso-hexestrol Strong ER agonist 
Zeralenone ER agonist 
Estrone Strong ER agonist 
Methyl testosterone ER agonist 
Coumestrol ER agonist 
Genistein Weak ER agonist/antagonist 
p-n-nonylphenol ER agonist/antagonist 
Bisphenol B ER agonist 
Diadzein Weak ER agonist 
4-cumylphenol Weak ER agonist 
Bisphenol A ER agonist 
o,p’-DDT Weak ER agonist/antagonist 
p,p’-methoxychlor Weak ER agonist 
Fenarimol --- 
Apigenen ER agonist 
Tamoxifen ER antagonist 
Kepone Binds to ER 
Butylbenzyl phthalate ER agonist 
4-hydroxytamoxifen ER antagonist 
Kaempferol ER agonist 
4-tert-octylphenol ER agonist 
p,p’-DDE --- 
Di-n-butyl phthalate ER agonist 
Flavone Weak ER antagonist 
Dexamethasone --- 
5α-dihydro-testosterone Weak ER agonist 
2,4,5-trichloro-phenoxyacetic acid Weak ER agonist 
Dibenzo[a,h]-anthracene --- 
ICI 182,780 ER antagonist 
Atrazine --- 
Progesterone --- 
Testosterone --- 
Corticosterone --- 
Phenobarbital --- 
Vinclozolin --- 
Cyproterone acetate --- 
Flutamide --- 
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Linuron --- 
Methyltrienolone --- 
Mifepristone --- 
Procymidone --- 
Clomphene citrate Binds to ER, selective estrogen receptor modulator 
Ethyl paraben Binds weakly to ER 
Norethynodrel Binds to ER 
Actinomycon D --- 
4-androstenedione --- 
2-sec-butylphenol --- 
Diethylhexyl phthalate Does not bind ER 
fadrozole --- 
Fluoroanthene --- 
Hydroxyflutamide --- 
Morin Binds weakly to ER 
Phenophtalin --- 
Propylthiouracil -- 
Sodium azide --- 
12-o-tetradecanoyl-phorbol-13-acetate --- 
Ammonium perchlorate --- 
Anastrole --- 
Apomorphine --- 
Bicalutamide --- 
CGS 18320B --- 
Cycloheximide --- 
Finasteride --- 
Fluoxymestrone --- 
Haloperidol --- 
Ketoconazole --- 
Medroxyprogesterone acetate --- 
Nilutamide --- 
Oxazepam --- 
Pimozide --- 
Reserpine --- 
Spironolactone --- 
L-thyroxine --- 
17β-trenbolone --- 
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Appendix B: Media Recipes 
LB Agar Plates (1L) 
~Add the following to 1L Ultrapure H2O: 
1.5% Agar  15g 
1% Tryptone  10g   
1% NaCl – 10g 
0.5% Yeast Extract – 5g 
~Adjust pH to 7.0  
~Autoclave solution 
~Let cool until touchable (think hot coffee)  
~Add the following: 
50 µg/mL Thymine – 25ml 2mg/mL Thymine  
200 µg/mL AMP  8ml AMP25 
~Dispense into plates and let cool until firm 
~Store plates at 4ºC 
 
AMP25 – 25mg/mL Ampicillin (50mL) 
~Dissolve in diH2O 
~Sterilize by filtration 
~Store at -20ºC 
 
2mg/mL Thymine (200mL) 
~Dissolve in diH2O 
~Sterilize by autoclaving 
~Store at room temperature 
 
LB (1L) 
~Add the following to 1L Ultrapure H2O 
1% Tryptone  10g   
1% NaCl  10g 
0.5% Yeast Extract  5g 
~Adjust pH to 7.0  
~Sterilize by autoclaving 
~Store at room temperature 
 
0.1 M CaCl2 (200mL) 
~Dissolve 2.94g in 200mL diH2O 
~Sterilize by autoclaving 
~Store at 4ºC 
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Minimal Davis Broth (1L) 
~Add the following to 1L diH2O: 
Dipotassium phosphate – 35g 
Monopotassium phosphate – 10g 
Sodium citrate – 2.5g 
Magnesium Sulfate – 0.5g 
Ammonium Sulfate – 5g 
~Sterilize by autoclaving 
~Store at 4ºC 
 
10% Casamino Acid (200mL) 
~Dissolve 20g Casamino Acid into 200mL diH2O 
~Sterilize by vacuum filtration 
~Store at 4ºC 
 
20% Glucose (200mL) 
~Dissolve 40g Dextrose into 200mL diH2O 
~Sterilize by vacuum filtration 
~Store at 4ºC 
 
1% Thiamine HCl (100mL) 
~Dissolve 1g Thiamine HCl into 100mL diH2O 
~Sterilize by vacuum filtration 
~Store at 4ºC 
 
Thy Pool (200mL) 
~Dissolve the following in 200mL diH2O: 
L-Arg – 400mg 
L-His – 400mg  
L-Leu – 400mg 
L-Meth – 400mg 
L-Pro – 400mg 
L-Thr – 400mg 
~Sterilize by vacuum filtration 
~Store at 4ºC 
 
-Thy (1L) 
~Add the following to 761mL Ultrapure H2O:  
20% Glucose – 10ml 
Thy Pool – 10ml 
10% Casamino Acid – 10ml 
1% Thiamine HCl - 200μl 
0.1M CaCl2 – 1ml 
Minimum Davis Broth – 200ml  
200 µg/mL AMP  8ml AMP25 
~Store at 4ºC 
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Appendix B: Curve-Fitting Programs 
% ICCVAM Data Processing Program 
% This program reads an Excel .xls file with multiple sheets 
% And Creates Dose-response curves 
  
% Written for n=3 
% Load data from sheet 
sheet1=xlsread('01102012.xls',1); 
sheet2=xlsread('01102012.xls',2); 
sheet3=xlsread('01102012.xls',3); 
  
% Name controls, compounds in plate 
controls={'E2', 'Genestein', 'ICI182780'}; 
compounds={'compound1', 'compound2', 'compound3', 'compound4', 'compound5'}; 
  
% Make arrays for each compound 
% Compound 1 
compound1_1=sheet1(2,:); 
compound1_2=sheet2(2,:); 
compound1_3=sheet3(2,:); 
% Compound 2 
compound2_1=sheet1(3,:); 
compound2_2=sheet2(3,:); 
compound2_3=sheet3(3,:); 
% Compound 3 
compound3_1=sheet1(4,:); 
compound3_2=sheet2(4,:); 
compound3_3=sheet3(4,:); 
% Compound 4 
compound4_1=sheet1(5,:); 
compound4_2=sheet2(5,:); 
compound4_3=sheet3(5,:); 
% Compound 5 
compound5_1=sheet1(6,:); 
compound5_2=sheet2(6,:); 
compound5_3=sheet3(6,:); 
% Compound 6 
compound6_1=sheet1(7,:); 
compound6_2=sheet2(7,:); 
compound6_3=sheet3(7,:); 
% Compound 7 
compound7_1=sheet1(8,:); 
compound7_2=sheet2(8,:); 
compound7_3=sheet3(8,:); 
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% Compound 8 
compound8_1=sheet1(9,:); 
compound8_2=sheet2(9,:); 
compound8_3=sheet3(9,:); 
  
% Write to files 
concentration=[1e-4; 2e-5; 4e-6; 8e-7; 1.6e-7; 3.2e-8; 6.4e-9; 1.28e-9; 2.56e-10; 5.12e-11; 
1.024e-11; 2.048e-12]; 
% Write file 1 
xlswrite('compound1.xls',concentration,'a1:a12') 
xlswrite('compound1.xls',rot90(compound1_1,3),'b1:b12') 
xlswrite('compound1.xls',rot90(compound1_2,3),'c1:c12') 
xlswrite('compound1.xls',rot90(compound1_3,3),'d1:d12') 
% Write file 2 
xlswrite('compound2.xls',concentration,'a1:a12') 
xlswrite('compound2.xls',rot90(compound2_1,3),'b1:b12') 
xlswrite('compound2.xls',rot90(compound2_2,3),'c1:c12') 
xlswrite('compound2.xls',rot90(compound2_3,3),'d1:d12') 
% Write file 3 
xlswrite('compound3.xls',concentration,'a1:a12') 
xlswrite('compound3.xls',rot90(compound3_1,3),'b1:b12') 
xlswrite('compound3.xls',rot90(compound3_2,3),'c1:c12') 
xlswrite('compound3.xls',rot90(compound3_3,3),'d1:d12') 
% Write file 4 
xlswrite('compound4.xls',concentration,'a1:a12') 
xlswrite('compound4.xls',rot90(compound4_1,3),'b1:b12') 
xlswrite('compound4.xls',rot90(compound4_2,3),'c1:c12') 
xlswrite('compound4.xls',rot90(compound4_3,3),'d1:d12') 
% Write file 5 
xlswrite('compound5.xls',concentration,'a1:a12') 
xlswrite('compound5.xls',rot90(compound5_1,3),'b1:b12') 
xlswrite('compound5.xls',rot90(compound5_2,3),'c1:c12') 
xlswrite('compound5.xls',rot90(compound5_3,3),'d1:d12') 
% Write file 6 
xlswrite('compound6.xls',concentration,'a1:a12') 
xlswrite('compound6.xls',rot90(compound6_1,3),'b1:b12') 
xlswrite('compound6.xls',rot90(compound6_2,3),'c1:c12') 
xlswrite('compound6.xls',rot90(compound6_3,3),'d1:d12') 
% Write file 7 
xlswrite('compound7.xls',concentration,'a1:a12') 
xlswrite('compound7.xls',rot90(compound7_1,3),'b1:b12') 
xlswrite('compound7.xls',rot90(compound7_2,3),'c1:c12') 
xlswrite('compound7.xls',rot90(compound7_3,3),'d1:d12') 
% Write file 8 
xlswrite('compound8.xls',concentration,'a1:a12') 
xlswrite('compound8.xls',rot90(compound8_1,3),'b1:b12') 
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xlswrite('compound8.xls',rot90(compound8_2,3),'c1:c12') 
xlswrite('compound8.xls',rot90(compound8_3,3),'d1:d12') 
  
% Graph files 
% Need associated sigmoid processing files ec50, ec50find, hillcal, 
% init_coeffs and sigmoid 
% Creates five graphs 
  
% Graph each compound 
for n=1:1:5 
    figure; 
    hold on; 
    ec50find('compound6.xls','k','ks') 
    ec50find('compound7.xls','b','bs') 
    ec50find('compound8.xls','r','rs') 
    ec50find(strcat('compound',int2str(n),'.xls'),'g','gs') 
    leg=legend(controls{1},'',controls{2},'',controls{3},'',compounds{n},'') 
    set(leg,'FontSize',15) 
    titlevar=strcat(compounds{n},' Growth-Concentration Curve at 34 C for 19 Hours 11/11/11'); 
    title(titlevar, 'FontSize',20); 
end 
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function EC50=EC50Find(file,a,b) 
%EC50Find takes a string input, the name of the excel file where the data 
%is stored, and returns the EC50 value and a plot of the data with the 
%appropriate sigmoid fit. 
  
if ~ischar(file) 
    error('The input file name must be a string'); 
end 
  
data=xlsread(file); 
  
concentrations=data(:,1); 
responses=data(:,2:end); 
MeanResponse=mean(responses,2); 
EBar=std(responses,0,2); 
  
con=log10(concentrations); 
results=ec50(con,MeanResponse); 
r=results; 
  
Min=min(concentrations); 
Max=max(concentrations); 
lowlim=floor(log10(Min))-1; 
highlim=ceil(log10(Max))+1; 
x=logspace(lowlim,highlim,1000); 
X=log10(x); 
  
y=r(1)+(r(2)-r(1))./(1+10.^((r(3)-X)*r(4))); 
  
% a='b'; 
     m=plot(x,y,a); 
    hold all 
    n=errorbar(concentrations,MeanResponse,EBar,b); 
    h=gca; 
    set(h,'XScale','log') 
%     legend('Fit','Data','Location','SouthEast') 
    xlab=xlabel('Concentration (M)') 
    ylab=ylabel('Response') 
    set(xlab,'FontSize',15) 
    set(ylab,'FontSize',15) 
%     hold off 
  
r(4) 
EC50=10^r(3) 
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function results=ec50(conc,responses) 
% EC50 Function to fit a dose-response data to a 4 parameter dose-response 
%   curve. 
%  
% Requirements: nlinfit function in the Statistics Toolbox 
%           and accompanying m.files: init_coeffs.m and sigmoid.m 
% Inputs: 1. a 1 dimensional array of drug concentrations 
%         2. the corresponding m x n array of responses  
% Algorithm: generate a set of initial coefficients including the Hill 
%               coefficient 
%            fit the data to the 4 parameter dose-response curve using 
%               nonlinear least squares 
% Output: a matrix of the 4 parameters 
%         results[m,1]=min 
%         results[m,2]=max 
%         results[m,3]=ec50 
%         results[m,4]=Hill coefficient 
% 
% Copyright 2004 Carlos Evangelista  
% send comments to CCEvangelista@aol.com 
% Version 1.0    01/07/2004 
  
[m,n]=size(responses); 
results=zeros(n,4); 
for i=1:n 
     response=responses(:,i); 
     initial_params=init_coeffs(conc,response); 
     [coeffs,r,J]=nlinfit(conc,response,'sigmoid',initial_params); 
%    disp (coeffs); 
     for j=1:4 
         results(i,j)=coeffs(j); 
     end 
end 
%disp (results); 
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function yhat=sigmoid(params4,x) 
% SIGMOID Function to fit data to a four parameter dose response curve 
% requires the nlinfit function of the statistics toolbox and a set of  
% initial parameters such as the one generated by init_coeffs.m. 
% This function is used by ec50.m 
% 
% Copyright 2004 Carlos Evangelista  
% send comments to CCEvangelista@aol.com 
% Version 1.0    01/07/2004 
  
min=params4(1); 
max=params4(2); 
ec=params4(3); 
hillc=params4(4); 
  
x1=x(:,1); 
  
yhat=min+(max-min)./(1+10.^((ec-x1)*hillc)); 
 
function [concentrations,MeanResponse,EBar,y,x,X]= hillcal(file) 
  
if ~ischar(file) 
    error('The input file name must be a string'); 
end 
  
 data=xlsread(file); 
  
concentrations=data(:,1); 
responses=data(:,2:end); 
MeanResponse=mean(responses,2); 
EBar=std(responses,0,2); 
  
con=log10(concentrations); 
results=ec50(con,MeanResponse); 
r=results; 
  
Min=min(concentrations); 
Max=max(concentrations); 
lowlim=floor(log10(Min))-1; 
highlim=ceil(log10(Max))+1; 
x=logspace(lowlim,highlim,1000); 
X=log10(x); 
  
y=r(1)+(r(2)-r(1))./(1+10.^((r(3)-X)*r(4))); 
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function init_params = init_coeffs(x,y) 
% INIT_COEFFS Function to generate the initial parameters for the 4 
% parameter dose response curve. 
% Requires an array of doses and an array of responses 
% This function is used by sigmoid.m and ec50.m 
% 
% Copyright 2004 Carlos Evangelista  
% send comments to CCEvangelista@aol.com 
% Version 1.0    01/07/2004 
  
parms=ones(1,4); 
parms(1)=min(y); 
parms(2)=max(y); 
parms(3)=(min(x)+max(x))/2; 
sizey=size(y); 
sizex=size(x); 
if (y(1)-y(sizey))./(x(2)-x(sizex))>0 
    parms(4)=(y(1)-y(sizey))./(x(2)-x(sizex)); 
else 
    parms(4)=1; 
end 
init_params=parms; 
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Appendix C: Dose-Response Curves for Initial Validation 
Biological Validation 
 
Figure 12: Initial dose-response curve for E2 
 
Figure 13: Initial dose-response curve for T3 
ERβ-H Dose-Response Curve – E2 - 34 C - 18 Hours - 8/22/11 
ERβ-H Dose-Response Curve  - T3 - 34 C - 18 Hours - 8/22/11 
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Figure 14: Initial dose-response curve for Triac 
Growth Time Determination 
 
Figure 15: Growth time determination curve for 12 hours 
ERβ-H Dose-Response Curve – Triac - 34 C - 18 Hours - 8/22/11 
ERβ-H Dose-Response Curve – E2 - 34 C - 12 Hours - 8/22/11 
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Figure 16: Growth time determination curve for 18 hours 
 
Figure 17: Growth time determination curve for 21 hours 
  
ERβ-H Dose-Response Curve – E2 - 34 C - 18 Hours - 8/22/11 
ERβ-H Dose-Response Curve – E2 - 34 C - 21 Hours - 8/22/11 
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Estrogen Sensitivity Test 
 
Figure 18: Estrogen sensitivity test for E2 
 
Figure 19:  Estrogen sensitivity test for bisphenol A 
 
10
-12
10
-10
10
-8
10
-6
10
-4
10
-2
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
Concentration (M)
R
e
s
p
o
n
s
e
10
-12
10
-10
10
-8
10
-6
10
-4
10
-2
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Concentration (M)
R
e
s
p
o
n
s
e
ERβ-H Dose-Response Curve – E2 - 34 C - 18 Hours - 8/29/11 
ERβ-H Dose-Response Curve – Bisphenol A - 34 C - 18 Hours - 8/29/11 
 43  
 
Figure 20:  Estrogen sensitivity test for meso-hexestrol 
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Appendix D: Liquid Handling Calibration Graphs 
Manual Pipetting Calibration Curve (n=8) 
 
Figure 21: Manual calibration curve 
Biomek 20-200 Microliter Tool Calibration (n=8) 
 
Figure 22: Robot calibration curve 
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Biomek 1-20 Microliter Tool Calibration (n=8) 
 
Figure 23: Robot calibration curve for lower concentrations 
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Appendix E: Full Screening Dose-Response Curves 
 
Figure 24: Dose-response curve for compound 1 
 
Figure 25:  Dose-response curve for compound 2 
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Figure 26:  Dose-response curve for compound 3 
 
Figure 27:  Dose-response curve for compound 4 
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Figure 28:  Dose-response curve for compound 5 
 
Figure 29:  Dose-response curve for compound 6 
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Figure 30:  Dose-response curve for compound 7 
 
Figure 31:  Dose-response curve for compound 8 
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Figure 32:  Dose-response curve for compound 9 
 
Figure 33:  Dose-response curve for compound 10 
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Figure 34:  Dose-response curve for compound 11 
 
Figure 35:  Dose-response curve for compound 12 
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Figure 36:  Dose-response curve for compound 13 
 
Figure 37:  Dose-response curve for compound 14 
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Figure 38:  Dose-response curve for compound 15 
 
Figure 39:  Dose-response curve for compound 16 
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Figure 40:  Dose-response curve for compound 17 
 
Figure 41:  Dose-response curve for compound 18 
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Figure 42:  Dose-response curve for compound 19 
 
Figure 43:  Dose-response curve for compound 20 
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Figure 44:  Dose-response curve for compound 21 
 
Figure 45:  Dose-response curve for compound 22 
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Figure 46:  Dose-response curve for compound 23 
 
Figure 47:  Dose-response curve for compound 24 
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Figure 48:  Dose-response curve for compound 25 
 
Figure 49:  Dose-response curve for compound 26 
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Figure 50:  Dose-response curve for compound 27 
 
Figure 51:  Dose-response curve for compound 28 
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Figure 52:  Dose-response curve for compound 29 
 
Figure 53:  Dose-response curve for compound 30 
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Appendix F: Full Screening Results 
Plate Number Compound Dose-Response Relationship Present EC50 (M) EC50 (μM) 
1 Compound 1 No N/A N/A 
 Compound 2 No N/A N/A 
 Compound 3 No N/A N/A 
 Compound 4 Yes 6.92*10
-9 
6.92*10
-3 
 Compound 5 No N/A N/A 
 E2 Yes 5.12*10
-7 
0.512 
 Genestein Yes 4.90*10
-7 
0.490 
 ICI 182,780 No N/A N/A 
2 Compound 6 No N/A N/A 
 Compound 7 Yes 3.57*10
-5 
35.7 
 Compound 8 No N/A N/A 
 Compound 9 Yes 4.91*10
-5 
49.1 
 Compound 10 No N/A N/A 
 E2 Yes 1.94*10
-8 
0.0194 
 Genestein Yes 2.81*10
-7 
0.281 
 ICI 182,780 No N/A N/A 
3 Compound 11 No N/A N/A 
 Compound 12 No N/A N/A 
 Compound 13 No N/A N/A 
 Compound 14 No N/A N/A 
 Compound 15 No N/A N/A 
 E2 Yes 1.84*10
-7 
0.184 
 Genestein Yes 1.39*10
-7 
0.139 
 ICI 182,780 No N/A N/A 
4 Compound 16 No N/A N/A 
 Compound 17 Yes 3.50*10
-5 
35.0 
 Compound 18 No N/A N/A 
 Compound 19 No N/A N/A 
 Compound 20 No N/A N/A 
 E2 Yes 2.54*10
-7 
0.254 
 Genestein Yes 3.29*10
-7 
0.329 
 ICI 182,780 No N/A N/A 
5 Compound 21 Yes 0.002 2000 
 Compound 22 No N/A N/A 
 Compound 23 No N/A N/A 
 Compound 24 Yes 2.76*10
-4 
274 
 Compound 25 Yes 2.86*10
-5 
28.6 
 E2 Yes 2.41*10
-7 
0.241 
 Genestein Yes 3.37*10
-7 
0.337 
 ICI 182,780 No N/A N/A 
6 Compound 26 No N/A N/A 
 Compound 27 No N/A N/A 
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 Compound 28 No N/A N/A 
 Compound 29 No N/A N/A 
 Compound 30 No N/A N/A 
 E2 Yes 1.94*10
-7 
0.194 
 Genestein Yes 1.76*10
-7 
0.176 
 ICI 182,780 No N/A N/A 
 
